CuraTeQ Biologics enters into agreement with STADA Arzneimittel AG
STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories
STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories
Subscribe To Our Newsletter & Stay Updated